WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

NCT07216651 | Completed

• 1 other identifier: CLM-OB-001
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.

Conditions

Obesity & Overweight

Keywords

Obesity; Overweight; GLP-1; Semaglutide

Outcome Measures

Primary Outcomes (1)

• Percentage of participants who persisted on semaglutide treatment over the study period

  The primary outcome is treatment persistence during the 3-month observation period, defined as the proportion of participants who remain on semaglutide treatment without discontinuation. Discontinuation will be defined as either a formal cessation of medication or the absence of a prescription renewal within the expected timeframe

  3 months

Secondary Outcomes (4)

• Number and percentage of participants discontinuing semaglutide due to unwanted side effects or other clinically significant reasons

  3 months

• Weight loss from baseline to end of study

  3 months

• Patients' experience of WeDosify and perceived impact of treatment using custom Patient-Reported Experience Measure (PREM) and Patient-Reported Outcome Measure (PROM) questionnaires at end of study

  3 months

• Healthcare Professional (HCP) user experience and perceived utility assessed by custom questionnaire at end of study (to include utilization and ease of use)

  3 months

Study Arms (1)

Observational semaglutide treated cohort

This research focuses on adult subjects who have recently been prescribed semaglutide (Wegovy) for obesity or overweight.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with Obesity or Overweight receiving semaglutide (Wegovy)

You may qualify if:

• Participants must be 18 years or older.
• Participants must have a diagnosis of either obesity or overweight.
• Participants must have initiated first-time semaglutide treatment within the past 4-12 weeks for the management of overweight or obesity, in line with United States Prescribing Information (USPI) and the clinical judgment of the responsible Healthcare Professional (HCP).
• Participants must have access to and be able to use suitable weighing scales to record their weight before or during consultations.
• Participants must provide written informed consent to participate in this study, including agreeing to adhere to the associated procedures.

You may not qualify if:

• Participants with conditions that the Healthcare Professional (HCP) deems would prevent effective use of weighing scales and accurate self-monitoring or reporting of body weight.
• Failure to satisfy the responsible Healthcare Professional (HCP) of fitness to participate for any other reason.

Sponsors & Collaborators

• Closed Loop Medicine: lead

Study Sites (1)

Amarillo Premier Research (an Objective Health Partnership)

Amarillo, Texas, 37067, United States

Location

MeSH Terms

Conditions

Obesity; Overweight

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Susan Neese, MD

  Amarillo Premier Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 10, 2025
• First Posted: October 14, 2025
• Study Start: September 23, 2025
• Primary Completion: February 27, 2026
• Study Completion: March 18, 2026
• Last Updated: March 19, 2026

Record last verified: 2026-03

Locations

US (1)